National Institute of Allergy and Infectious Diseases

The National Institute of Allergy and Infectious Diseases (NIAID) has released a statement, saying that the Data and Safety Monitoring Board (DSMB), an independent group of experts that advises US National Institute of Dental and Craniofacial Research, was concerned "that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data."

"Late Monday, the Data and Safety Monitoring Board (DSMB) notified NIAID, BARDA, and AstraZeneca that it was concerned by information released by AstraZeneca on initial data from its COVID-19 vaccine clinical trial,” the statement says. “The DSMB expressed concern that AstraZeneca may have included outdated information from that trial, which may have provided an incomplete view of the efficacy data. We urge the company to work with the DSMB to review the efficacy data and ensure the most accurate, up-to-date efficacy data be made public as quickly as possible.”

Dr. Anthony Fauci, NIAID Director and WH Coronavirus advisor, reports that there is no valid scientific data that shows hydroxychloroquine is an effective treatment for Covid-19.

"You look at the scientific data and the evidence. And the scientific data ... on trials that are valid, that were randomized and controlled in the proper way, all of those trials show consistently that hydroxychloroquine is not effective in the treatment of coronavirus disease or Covid-19," Fauci told MSNBC just a day after President Trump promoted hydroxychloroquine as a working treatment. Trump had claimed that many doctors thought the drug was "extremely good" and that it was safe to take. As of now, there is no FDA-approved drug for the treatment of Covid-19.

The director of the United States National Institute of Allergy and Infectious Diseases Dr. Anthony Faucy has said that he doesn't understand why a federal stay-at-home order hasn't been implemented yet and advocated to mandate such order saying "We really should be".